Trial Profile
A non-comparative, multicenter, open-label study in patients with first recurrence of glioblastoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Glioblastoma; Gliosarcoma
- Focus Therapeutic Use
- Sponsors Ono Pharmaceutical
- 24 Feb 2017 Status changed from recruiting to active, no longer recruiting.
- 09 Jun 2016 New trial record